Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annexon, Inc. - common stock (NQ:ANNX)

5.215 +0.095 (+1.86%)
Streaming Delayed Price Updated: 2:59 PM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annexon, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Nasdaq Gains 100 Points; CarMax Earnings Top Views ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.37% to 37,218.15 while the NASDAQ rose 0.73% to 14,885.76.... 
Via Benzinga
Topics Stocks
News headline image
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
News headline image
Why Is Complement-Mediated Focused Annexon Stock Trading Higher Today? ↗
On Wednesday, Annexon Inc (NASDAQ: ANNX) reported results from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of ANX1502 that targets the active form... 
Via Benzinga
News headline image
Recap: Annexon Q3 Earnings ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Annexon ↗
 
Via Benzinga
News headline image
Analyst Ratings for Annexon ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! 
Via InvestorPlace
News headline image
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
From Annexon Biosciences
Via GlobeNewswire
News headline image
Analyst Expectations for Annexon's Future ↗
 
Via Benzinga
News headline image
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET 
From Annexon Biosciences
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2023 ↗
 
Via Benzinga
News headline image
Crude Oil Drops Sharply; Best Buy Earnings Top Expectations ↗
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining more than 200 oints on Thursday. The Dow traded down 0.02% to 32,793.29 while the NASDAQ rose 1.78% to 12,706.89.... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.